Dosing & Uses
Dosage Forms & Strengths
capsule
- 750mg (Colazal)
tablet (dsc)
- 1.1g (Giazo)
Ulcerative Colitis
Colazal: 3 capsules (2.25 g total) PO TID (total dose 6.75 g/day x 8-12 weeks
Giazo (males): 3 tablets (3.3 g total) PO BID (total dose 6.6 g/day) x 8 weeks
Dosing Considerations
Giazo: Locally acting aminosalicylate indicated for the treatment of mildly to moderately active ulcerative colitis in male patients 18 years of age and older; effectiveness in female patients was not demonstrated in clinical trials
Administration
May take with or without food
Colazal: Swallow capsule whole, or open capsule, sprinkle contents on applesauce and chew or swallow immediately
Dosage Forms & Strengths
capsule
- 750mg (Colazal)
Ulcerative Colitis
Giazo: Safety and efficacy not established in children <18 years
5-17 years (Colazal)
- <5 years: Safety and efficacy not established
- May initiate at either 6.75 g/day or 2.25 g/day
- 3 capsules (2.25 g total) PO TID (total dose 6.75 g/day) x8 weeks, OR
- 1 capsule (750 mg) PO TID (total dose 2.25 g/day) for up to 8 weeks
Administration
May take with or without food
Colazal: Swallow whole, or open capsule, sprinkle contents on applesauce and chew or swallow immediately
Interactions
Interaction Checker
No Results

Contraindicated
Serious - Use Alternative
Significant - Monitor Closely
Minor

Adverse Effects
>10%
Headache (15% peds)
Abdominal pain (13% peds )
Vomiting (10% peds)
1-10% (Adults)
Headache (8%)
Abdominal pain (6%)
Nausea (5%)
Diarrhea (5%)
Respiratory infection (4%)
Arthralgia (4%)
Vomiting (4%)
Fatigue (2%)
Insomnia (2%)
Cough (2%)
Pharyngitis (2%)
Rhinitis (2%)
Dyspepsia (2%)
Anorexia (2%)
Flatulence (2%)
Fever (2%)
Constipation (1%)
Cramps (1%)
Ulcerative colitis exacerbation (1%)
Flu like syndrome (1%)
Myalgia (1%)
UTI (1%)
Xerostomia (1%)
1-10% (Pediatrics)
Diarrhea (9%)
Fever (6%)
Ulcerative colitis exacerbation (6%)
Pharyngitis (6%)
Fatigue (4%)
Flu like syndrome (4%)
Nausea (4%)
Hematochezia (4%)
Cough (3%)
Dysmenorrhea (3%)
Stomatitis (3%)
Postmarketing Reports
Cardiovascular and vascular: Myocarditis, pericarditis, vasculitis
Respiratory: Alveolitis, pleural effusion, pneumonia (with and without eosinophilia)
Gastrointestinal: Pancreatitis
Renal: Interstitial nephritis, renal failure, nephrolithiasis
Hepatobiliary disorders: Elevated liver enzymes (AST, ALT, GGT, LDH, alkaline phosphatase), elevated bilirubin, jaundice, cholestatic jaundice, cirrhosis, hepatocellular damage including liver necrosis and liver failure, Kawasaki-like syndrome including hepatic dysfunction; some of these cases were fatal
Warnings
Contraindications
Hypersensitivity to salicylates, balsalazide, mesalamine
Cautions
Risk of exacerbation of ulcerative colitis
Assess renal function at beginning of treatment and periodically during treatment; evaluate risks and benefits in patients with known renal impairment or taking nephrotoxic drugs; monitor renal function.
Mesalamine-induced acute intolerance syndrome symptoms may be difficult to distinguish from exacerbation of ulcerative colitis; monitor for worsening symptoms; discontinue treatment if acute intolerance syndrome suspected
Hypersensitivity reactions, including myocarditis and pericarditis, reported; evaluate patients immediately and discontinue if hypersensitivity reaction is suspected
Hepatic failure reported; evaluate risks and benefits in patients with known liver impairment
Photosensitivity reported; advice patients with pre-existing skin conditions to avoid sun exposure, wear protective clothing, and use a broad-spectrum sunscreen when outdoors
Nephrolithiasis reported; stones containing mesalamine, the active moiety, are undetectable by standard radiography or computed tomography (CT). ensure adequate fluid intake during treatment
Use of mesalamine may lead to spuriously elevated test results when measuring urinary normetanephrine by liquid chromatography with electrochemical detection
Pregnancy & Lactation
Pregnancy
Published data from meta-analyses, cohort studies and case series on use of mesalamine, the active moiety of the drug, during pregnancy have not reliably informed an association with mesalamine and major birth defects, miscarriage, or adverse maternal or fetal outcomes
Published data suggest that increased disease activity is associated with risk of developing adverse pregnancy outcomes in women with ulcerative colitis; adverse pregnancy outcomes include preterm delivery (before 37 weeks of gestation), low birth weight (less than 2500 g) infants, and small for gestational age at birth
Animal data
- There are adverse effects on maternal and fetal outcomes associated with ulcerative colitis in pregnancy; in animal reproduction studies, there were no adverse developmental effects observed after oral administration in pregnant rats and rabbits during organogenesis at doses up to 2.4 and 4.7 times, respectively, the maximum recommended human dose (MRHD)
Lactation
Data from published literature report presence of mesalamine and metabolite, N acetyl-5 aminosalicylic acid, in human milk in small amounts with relative infant doses (RID) of 0.1% or less for mesalamine; there are case reports of diarrhea in breastfed infants exposed to mesalamine; there is no information on effects of drug on milk production
Lack of clinical data during lactation precludes a clear determination of risk of drug to an infant during lactation; therefore, developmental and health benefits of breastfeeding should be considered along with mother’s clinical need for drug and any potential adverse effects on breastfed child from drug or from underlying maternal condition
Pregnancy Categories
A: Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.
B: May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk. C: Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done. D: Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk. X: Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist. NA: Information not available.Pharmacology
Mechanism of Action
Metabolized to mesalamine by intestinal flora
Mesalamine (5-aminosalicylic acid) has anti-inflammatory effect; active component of sulfasalazine, specific MOA unknown; probably inhibits prostaglandin & leukotrienes synthesis & release in colon
Absorption
Bioavailability: Low absorption
Onset: 10 days to 2 wk
Peak plasma time: 1-2 hr
Distribution
Protein bound: 99%
Vd: mesalamine: 0.2 L/kg
Metabolism
Following oral administration, balsalazide passes intact into colon where it is cleaved by intestinal flora to form mesalamine and 4-aminobenzoyl-b-alanine
Mesalamine is rapidly acetylated in colon wall and liver, independent of pt. acetylator status, into N-acetyl-5-aminosalycylic acid
Metabolites: mesalamine (active), N-acetyl-5-aminosalycylic acid (inactive), 4-aminobenzoyl-b-alanine (inactive)
Elimination
Half-life: Undetermined due to large intersubjective variability
Excretion: Feces (as metabolites) >65%; urine (as metabolites) >25%
Images
Patient Handout
Formulary
Adding plans allows you to compare formulary status to other drugs in the same class.
To view formulary information first create a list of plans. Your list will be saved and can be edited at any time.
Adding plans allows you to:
- View the formulary and any restrictions for each plan.
- Manage and view all your plans together – even plans in different states.
- Compare formulary status to other drugs in the same class.
- Access your plan list on any device – mobile or desktop.